Key statistics
On Monday, Pharvaris NV (PHVS:NSQ) closed at 28.00, -6.03% below its 52-week high of 29.80, set on Dec 04, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 28.10 |
|---|---|
| High | 28.61 |
| Low | 27.74 |
| Bid | 26.70 |
| Offer | 29.44 |
| Previous close | 28.39 |
| Average volume | 103.87k |
|---|---|
| Shares outstanding | 64.06m |
| Free float | 42.30m |
| P/E (TTM) | -- |
| Market cap | 1.82bn USD |
| EPS (TTM) | -3.45 USD |
Data delayed at least 15 minutes, as of Mar 02 2026 21:00 GMT.
More ▼
- Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026
- Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting
- Pharvaris Outlines 2026 Strategic Priorities
- Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks
- Pharvaris Reports Third Quarter 2025 Financial Results and Provides Business Update
- Data Supporting the Potentially Differentiated Pharvaris Portfolio Presented at ACAAI 2025 Annual Scientific Meeting
- Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting
- Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update
- Pharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
More ▼
